2024

• Elias, M., Fatima, S., Mann, T., Karan, S., Mikhael, M., De Souza, P., Gordon, C., Scott, K., Aldrich-Wright, J. (2024). Anticancer Effect of PtIIPHENSS, PtII5MESS, PtII56MESS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer. Cancers, 16(14). [More Information]

2023

• Gao, B., Voskoboynik, M., Cooper, A., Wilkinson, K., Hoon, S., Hsieh, C., Cai, S., Tian, Y., Bao, J., Ma, N., et al (2023). A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors. Cancer. [More Information]
• Redwood, L., Saarinen, K., Ivers, R., Garne, D., De Souza, P., Bonney, A., Rhee, J., Mullan, J., Thomas, S. (2023). Alcohol consumption and health-related quality of life in regional, rural and metropolitan Australia: analysis of cross-sectional data from the Community Health and Rural/Regional Medicine (CHARM) study. Quality of Life Research. [More Information]
• Gano, C., Fatima, S., Failes, T., Arndt, G., Sajinovic, M., Mahns, D., Saedisomeolia, A., Coorssen, J., Bucci, J., De Souza, P., et al (2023). Anti-cancer potential of synergistic phytochemical combinations is influenced by the genetic profile of prostate cancer cell lines. Frontiers in Nutrition, 10. [More Information]
• Lim, S., Chua, W., Ng, W., Ip, E., Marques, T., Tran, N., Gama-Carvalho, M., Asghari, R., Henderson, C., Ma, Y., et al (2023). Circulating Tumour Cell Associated MicroRNA Profiles Change during Chemoradiation and Are Predictive of Response in Locally Advanced Rectal Cancer. Cancers, 15(16). [More Information]

2022

• Hnit, S., Yao, M., Xie, C., Bi, L., Wong, M., Liu, T., De Souza, P., Li, Z., Dong, Q. (2022). Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells. Discover Oncology, 13(1). [More Information]
• Young, F., Becker, T., Nimir, M., Opperman, T., Chua, W., Balakrishnar, B., de Souza, P., Ma, Y. (2022). Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR. Journal of Clinical Medicine, 11.0 (1). [More Information]
• Khan, T., Lock, J., Ma, Y., Harman, D., De Souza, P., Chua, W., Balakrishnar, B., Scott, K., Becker, T. (2022). Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells. Scientific Reports, 12.0 (1). [More Information]
• Fatima, S., Ma, Y., Safrachi, A., Haider, S., Spring, K., Vafaee, F., Scott, K., Roberts, T., Becker, T., de Souza, P. (2022). Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers, 14.0 (7). [More Information]
• Sareen, H., Ma, Y., Becker, T., Roberts, T., de Souza, P., Powter, B. (2022). Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 23.0 (16). [More Information]
• Rottey, S., Clarke, J., Aung, K., Machiels, J., Markman, B., Heinhuis, K., Millward, M., Lolkema, M., Patel, S., De Souza, P., et al (2022). Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 28.0 (1), 95-105. [More Information]
• Jeffreys, S., Becker, T., Khan, S., Soon, P., Neubauer, H., de Souza, P., Powter, B. (2022). Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 13.0. [More Information]
• Khan, T., Becker, T., Scott, K., Descallar, J., De Souza, P., Chua, W., Ma, Y. (2022). Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 12.0. [More Information]
• De Souza, P., Aslan, P., Clark, W., Nour, R., de Silva, S. (2022). RESIRT: A Phase 1 Study of Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres in Patients With Primary Renal Cell Carcinoma. Clinical Genitourinary Cancer, 20.0 (5), 442-451. [More Information]
• Lai, H., Ho, U., James, A., de Souza, P., Roberts, T. (2022). RNA metabolism and links to inflammatory regulation and disease. Cellular and Molecular Life Sciences, 79.0 (1). [More Information]

2021

• Garrett, C., Becker, T., Lynch, D., Po, J., Xuan, W., Scott, K., De Souza, P. (2021). Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome. PloS One, 16.0 (6 June). [More Information]
• Piha-Paul, S., Thein, K., de Souza, P., Kefford, R., Gangadhar, T., Smith, C., Schuster, S., Zamboni, W., Dees, C., Markman, B. (2021). First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational New Drugs, 39.0 (4), 1047-1056. [More Information]
• Cameron, B., Webber, K., Li, H., Bennett, B., Boyle, F., de Souza, P., Wilcken, N., Lynch, J., Friedlander, M., Goldstein, D., et al (2021). Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. Brain, Behavior, & Immunity - Health, 10.0. [More Information]
• Scott, K., Mann, T., Fatima, S., Sajinovic, M., Razdan, A., Kim, R., Cooper, A., Roohullah, A., Bryant, K., Gamage, K., Church, W., Dong, Q., et al (2021). Human group iia phospholipase A2 —three decades on from its discovery. Molecules, 26(23), 7267. [More Information]
• Powter, B., Jeffreys, S., Sareen, H., Cooper, A., Brungs, D., Po, J., Roberts, T., Koh, E., Scott, K., Sajinovic, M., et al (2021). Human TERT promoter mutations as a prognostic biomarker in glioma. Journal of Cancer Research and Clinical Oncology, 147.0(4), 1007-1017. [More Information]
• Lai, H., James, A., Luff, J., de Souza, P., Quek, H., Ho, U., Lavin, M., Roberts, T. (2021). Regulation of RNA degradation pathways during the lipopolysaccharide response in Macrophages. Journal of Leukocyte Biology, 109.0(3), 593-603. [More Information]

2020

• Wimmer, M., Zauner, R., Ablinger, M., Pinõ´n-Hofbauer, J., Guttmann-Gruber, C., Reisenberger, M., Lettner, T., Niklas, N., Proell, J., Sajinovic, M., et al (2020). A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas. Cell Communication and Signaling, 18.0 (1). [More Information]
• Ho, V., Chung, L., Singh, A., Lea, V., Abubakar, A., Lim, S., Chua, W., Ng, W., Lee, M., Roberts, T., et al (2020). Aberrant expression of RAD52, its prognostic impact in rectal cancer and association with poor survival of patients. International Journal of Molecular Sciences, 21.0 (5). [More Information]
• Toh, J., Lim, S., MacKenzie, S., de Souza, P., Bokey, L., Chapuis, P., Spring, K. (2020). Association Between Microsatellite Instability Status and Peri-Operative Release of Circulating Tumour Cells in Colorectal Cancer. Cells, 9(2), 1-13. [More Information]
• Reardon, D., Brandes, A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M., Roth, P., Bähr, O., et al (2020). Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6.0(7), 1003-1010. [More Information]
• Jeffreys, S., Powter, B., Balakrishnar, B., Mok, K., Soon, P., Franken, A., Neubauer, H., de Souza, P., Becker, T. (2020). Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability. Cells, 9.0(9). [More Information]
• Lynch, D., Powter, B., Po, J., Cooper, A., Garrett, C., Koh, E., Sheridan, M., van Gelder, J., Darwish, B., Mckechnie, S., et al (2020). Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting. Applied Sciences, 10.0 (9). [More Information]
• Kato, H., De Souza, P., Kim, S., Lickliter, J., Naito, Y., Park, K., Kumar, S., Mugundu, G., Bang, Y. (2020). Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study. Targeted Oncology, 15.0 (1), 75-84. [More Information]
• Ackland, S., Michael, M., de Souza, P., Martin, J., Clarke, S., Francis, K., Karapetis, C., Gurney, H. (2020). Science and art of anticancer drug dosing: nine steps to personalised therapy. Internal Medicine Journal, 50(8), 992-996. [More Information]
• Tjokrowidjaja, A., Goldstein, D., Hudson, M., Lord, S., Gebski, V., Clarke, S., de Souza, P., Motzer, R., Lee, C. (2020). The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. Acta Oncologica, 59(1), 20-27. [More Information]
• Khan, T., Scott, K., Becker, T., Lock, J., Nimir, M., Ma, Y., de Souza, P. (2020). The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player? Prostate Cancer, 2020.0. [More Information]
• Sareen, H., Garrett, C., Lynch, D., Powter, B., Brungs, D., Cooper, A., Po, J., Koh, E., Vessey, J., Mckechnie, S., et al (2020). The role of liquid biopsies in detecting molecular tumor biomarkers in brain cancer patients. Cancers, 12.0 (7), 1-16. [More Information]
• Hnit, S., Yao, M., Xie, C., Ge, G., Bi, L., Jin, S., Jiao, L., Xu, L., Long, L., Nie, H., Rogers, L., Suchowerska, N., Dong, Q., et al (2020). Transcriptional regulation of G2/M regulatory proteins and perturbation of G2/M Cell cycle transition by a traditional Chinese medicine recipe. Journal of Ethnopharmacology, 251, 1-12. [More Information]

2019

• Clingan, P., Ackland, S., Brungs, D., De Souza, P., Aghmesheh, M., Garg, M., Ranson, R., Parker, S., Jokela, R., Ranson, M. (2019). First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. Asia-Pacific Journal of Clinical Oncology, 15.0 (3), 151-157. [More Information]
• Po, J., Ma, Y., Balakrishna, B., Brungs, D., Azimi, F., de Souza, P., Becker, T. (2019). Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PloS One, 14.0 (2). [More Information]
• Panizza, B., De Souza, P., Cooper, A., Roohullah, A., Karapetis, C., Lickliter, J. (2019). Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine, 50.0, 433-441. [More Information]
• Ding, P., Becker, T., Bray, V., Chua, W., Ma, Y., Xu, B., Lynch, D., de Souza, P., Roberts, T. (2019). Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Thoracic Cancer, 10.0 (10), 1879-1884. [More Information]
• Ding, P., Becker, T., Bray, V., Chua, W., Ma, Y., Lynch, D., Po, J., Luk, A., Caixeiro, N., de Souza, P., et al (2019). The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study. Lung Cancer, 134.0, 187-193. [More Information]

2018

• Brungs, D., Lynch, D., Luk, A., Minaei, E., Ranson, M., Aghmesheh, M., Vine, K., Carolan, M., Jaber, M., de Souza, P., et al (2018). Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer. World Journal of Gastroenterology, 24.0 (7), 810-818. [More Information]
• Campbell, D., Lund, M., Nocon, A., Cozzi, P., Frydenberg, M., de Souza, P., Schiller, B., Beebe-Dimmer, J., Ruterbusch, J., Walsh, B. (2018). Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PloS One, 13.0 (4). [More Information]
• Po, J., Roohullah, A., Lynch, D., deFazio, A., Harrison, M., Harnett, P., Kennedy, C., de Souza, P., Becker, T. (2018). Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. Journal of Circulating Biomarkers, 7, 1-10. [More Information]
• Razdan, A., de Souza, P., Roberts, T. (2018). Role of microRNAs in treatment response in prostate cancer. Current Cancer Drug Targets, 18.0 (10), 929-944. [More Information]
• Brungs, D., Aghmesheh, M., de Souza, P., Carolan, M., Clingan, P., Rose, J., Ranson, M. (2018). Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 17.0 (3), e549-e555. [More Information]

2017

• Luk, A., Ma, Y., Ding, P., Young, F., Chua, W., Balakrishnar, B., Dransfield, D., de Souza, P., Becker, T. (2017). CTC-mRNA (AR-V7) analysis from blood samples—impact of blood collection tube and storage time. International Journal of Molecular Sciences, 18.0 (5). [More Information]
• Callari, M., Wong, S., Lu, H., Aldrich-Wright, J., De Souza, P., Stenzel, M. (2017). Drug induced self-assembly of triblock copolymers into polymersomes for the synergistic dual-drug delivery of platinum drugs and paclitaxel. Polymer Chemistry, 8.0(40), 6289-6299. [More Information]
• Ho, V., Chung, L., Singh, A., Lea, V., Revoltar, M., Lim, S., Tut, T., Ng, W., Lee, M., De Souza, P., et al (2017). Early postoperative low expression of RAD50 in rectal cancer patients associates with disease-free survival. Cancers, 9.0(12). [More Information]
• Brungs, D., Aghmesheh, M., de Souza, P., Ng, W., Chua, W., Carolan, M., Clingan, P., Healey, E., Rose, J., Tubaro, T., et al (2017). Sidedness is prognostic in locoregional colon cancer: An analysis of 9509 Australian patients. BMC Cancer, 17.0 (1). [More Information]
• Callari, M., De Souza, P., Rawal, A., Stenzel, M. (2017). The Effect of Drug Loading on Micelle Properties: Solid-State NMR as a Tool to Gain Structural Insight. Angewandte Chemie - International Edition, 56.0 (29), 8441-8445. [More Information]
• Del Re, M., Fogli, S., Derosa, L., Massari, F., De Souza, P., Crucitta, S., Bracarda, S., Santini, D., Danesi, R. (2017). The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews, 55.0, 71-82. [More Information]

2016

• Ma, Y., Luk, A., Young, F., Lynch, D., Chua, W., Balakrishnar, B., de Souza, P., Becker, T. (2016). Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies. International Journal of Molecular Sciences, 17.0 (8). [More Information]
• Caixeiro, N., Byun, H., Descallar, J., Levesque, J., De Souza, P., Soon Lee, C. (2016). Health professionals' opinions on supporting a cancer biobank: Identification of barriers to combat biobanking pitfalls. European Journal of Human Genetics, 24.0 (5), 626-632. [More Information]
• Ho, V., Chung, L., Revoltar, M., Lim, S., Tut, T., Abubakar, A., Henderson, C., Chua, W., Ng, W., Lee, M., et al (2016). MRE11 and ATM expression levels predict rectal cancer survival and their association with radiotherapy response. PloS One, 11.0 (12). [More Information]
• Toh, J., de Souza, P., Lim, S., Singh, P., Chua, W., Ng, W., Spring, K. (2016). The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Clinical Colorectal Cancer, 15(4), 285-291. [More Information]

2015

• Ryan, C., Smith, M., Fizazi, K., Saad, F., Mulders, P., Sternberg, C., Miller, K., Logothetis, C., Shore, N., Small, E., et al (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 16.0 (2), 152-160. [More Information]
• Lim, S., Spring, K., de Souza, P., Mackenzie, S., Bokey, L. (2015). Circulating tumour cells and circulating nucleic acids as a measure of tumour dissemination in non-metastatic colorectal cancer surgery. European Journal of Surgical Oncology, 41.0 (3), 309-314. [More Information]
• Choueiri, T., Figueroa, D., Fay, A., Signoretti, S., Liu, Y., Gagnon, R., Deen, K., Carpenter, C., Benson, P., Ho, T., et al (2015). Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial. Clinical Cancer Research, 21.0 (5), 1071-1077. [More Information]
• Scarano, W., De Souza, P., Stenzel, M. (2015). Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: A double act for the treatment of multidrug-resistant cancer. Biomaterials Science, 3.0(1), 163-174. [More Information]
• Saad, F., Shore, N., Van Poppel, H., Rathkopf, D., Smith, M., de Bono, J., Logothetis, C., De Souza, P., Fizazi, K., Mulders, P., et al (2015). Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: Post hoc analysis of study COU-AA-302. European Urology, 68.0 (4), 570-577. [More Information]
• Lim, S., Chua, W., Henderson, C., Ng, W., Shin, J., Chantrill, L., Asghari, R., Lee, C., Spring, K., de Souza, P. (2015). Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Critical Reviews in Oncology/Hematology, 96(1), 67-80. [More Information]
• Tognela, A., Spring, K., Becker, T., Caixeiro, N., Bray, V., Yip, P., Chua, W., Lim, S., de Souza, P. (2015). Predictive and prognostic value of circulating tumor cell detection in lung cancer: A clinician's perspective. Critical Reviews in Oncology/Hematology, 93(2), 90-102. [More Information]
• Morris, M., Molina, A., Small, E., De Bono, J., Logothetis, C., Fizazi, K., De Souza, P., Kantoff, P., Higano, C., Li, J., et al (2015). Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. Journal of Clinical Oncology, 33.0 (12), 1356-1363. [More Information]
• Sengupta, S., Grimison, P., Hayne, D., Williams, S., Chambers, S., de Souza, P., Stockler, M., McJannett, M., Toner, G., Davis, I. (2015). The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group - a new co-operative cancer trials group in genitourinary oncology. BJU International, 115(6), 856-858. [More Information]

2014

• Caixeiro, N., Kienzle, N., Lim, S., Spring, K., Tognela, A., Scott, K., de Souza, P., Becker, T. (2014). Circulating tumour cells - A bona fide cause of metastatic cancer. Cancer and Metastasis Reviews, 33.0 (2-3), 747-756. [More Information]
• Lim, S., Becker, T., Chua, W., Caixeiro, N., Ng, W., Kienzle, N., Tognela, A., Lumba, S., Rasko, J., de Souza, P., et al (2014). Circulating Tumour Cells and Circulating Free Nucleic Acid as Prognostic and Predictive Biomarkers in Colorectal Cancer. Cancer Letters, 346, 24-33. [More Information]
• Lim, S., Becker, T., Chua, W., Ng, W., de Souza, P., Spring, K. (2014). Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. Journal of Clinical Pathology, 67.0 (10), 848-853. [More Information]
• Mak, G., Chin, M., Nahar, N., de Souza, P. (2014). Cutaneous metastasis of prostate carcinoma treated with radiotherapy: A case presentation. BMC Research Notes, 7.0(1). [More Information]
• Tse, B., Jovanovic, L., Nelson, C., de Souza, P., Power, C., Russell, P. (2014). From Bench to Bedside: Immunotherapy for Prostate Cancer. BioMed Research International, 2014.0. [More Information]
• Becker, T., Caixeiro, N., Lim, S., Tognela, A., Kienzle, N., Scott, K., Spring, K., De Souza, P. (2014). New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use. International Journal of Cancer, 134.0(11), 2523-2533. [More Information]
• Lim, S., Delaney, G., Descallar, J., Sayaloune, P., Papadatos, G., de Souza, P. (2014). Outcomes of ethnic minority groups with node-positive, non-metastatic breast cancer in two tertiary referral canters in Sydney, Australia. PloS One, 9.0(4). [More Information]
• Callari, M., Aldrich-Wright, J., De Souza, P., Stenzel, M. (2014). Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment. Progress in Polymer Science, 39.0 (9), 1614-1643. [More Information]
• Rathkopf, D., Smith, M., De Bono, J., Logothetis, C., Shore, N., De Souza, P., Fizazi, K., Mulders, P., Mainwaring, P., Hainsworth, J., et al (2014). Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology, 66.0 (5), 815-825. [More Information]

2013

• Paz-Ares, L., Bálint, B., Van Meerbeeck, J., Wierzbicki, R., De Souza, P., Galimi, F., Haddad, V., Sabin, T., Hei, Y., Pan, Y., et al (2013). A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. Journal of Thoracic Oncology, 8.0(3), 329-337. [More Information]
• Ryan, C., Smith, M., De Bono, J., Molina, A., Logothetis, C., De Souza, P., Fizazi, K., Mainwaring, P., Piulats, J., Ng, S., et al (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368.0(2), 138-148. [More Information]
• Suttle, A., De Souza, P., Arumugham, T. (2013). Bayesian methods for pharmacokinetic/ pharmacodynamic modeling of pazopanib-induced increases in blood pressure and transaminases. The Journal of Clinical Pharmacology, 53.0 (4), 377-384. [More Information]
• Yee, G., De Souza, P., Khachigian, L. (2013). Current and potential treatments for cervical cancer. Current Cancer Drug Targets, 13.0 (2), 205-220. [More Information]
• Lim, S., de Souza, P. (2013). Imatinib in neurofibromatosis type 2. BMJ Case Reports. [More Information]
• Motzer, R., Hutson, T., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., De Souza, P., Merchan, J., et al (2013). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369.0(8), 722-731. [More Information]

2012

• Coupe, N., Harrison, M., Chua, W., de Souza, P. (2012). Biomarkers for tyrosine kinase inhibitors in renal cell cancer. Translational Andrology and Urology, 1.0(4), 216-222. [More Information]

2011

• De Souza, P., Saad, F. (2011). Bone health in prostate cancer. Expert Review of Endocrinology & Metabolism, 6.0(3), 317-321. [More Information]
• Manners, S., Galettis, P., de Souza, P. (2011). Conditions causing gemcitabine crystallization. Journal of Oncology Pharmacy Practice, 17(4), 395-399. [More Information]
• Xu, C., Bing, N., Ball, H., Rajagopalan, D., Sternberg, C., Hutson, T., De Souza, P., Xue, Z., McCann, L., King, K., et al (2011). Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. Journal of Clinical Oncology, 29.0 (18), 2557-2564. [More Information]
• Howes, J., de Souza, P., West, L., Huang, L., Howes, L. (2011). Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. BMC Clinical Pharmacology, 11.0. [More Information]
• Li, S., de Souza, P. (2011). Ras isoprenylation and pAkt inhibition by zoledronic acid and fluvastatin enhances paclitaxel activity in T24 bladder cancer cells. Cancers, 3.0(1), 662-674. [More Information]
• Metharom, E., Galettis, P., Manners, S., Jelinek, M., Liauw, W., De Souza, P., Hoskins, J., Links, M. (2011). The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. Asia-Pacific Journal of Clinical Oncology, 7.0(1), 65-74. [More Information]

2010

• de Souza, P., North, S., Bolger, G., Spiridonidis, H., Lim, R., Khoo, K., Phillips, J., Fujimori, M. (2010). A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. Asia-Pacific Journal of Clinical Oncology, 6.0(4), 292-297. [More Information]
• de Souza, P., Russell, P., Kearsley, J., Howes, L. (2010). Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutrition Reviews, 68.0 (9), 542-555. [More Information]
• Hutson, T., Davis, I., Machiels, J., De Souza, P., Rottey, S., Hong, B., Epstein, R., Baker, K., McCann, L., Crofts, T., et al (2010). Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 28.0 (3), 475-480. [More Information]
• Yang, S., de Souza, P., Alemao, E., Purvis, J. (2010). Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α. British Journal of Cancer, 102.0(10), 1456-1460. [More Information]

2009

• Figlin, R., de Souza, P., McDermott, D., Dutcher, J., Berkenblit, A., Thiele, A., Krygowski, M., Strahs, A., Feingold, J., Boni, J., et al (2009). Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α. Cancer, 115.0(16), 3651-3660. [More Information]
• Dutcher, J., de Souza, P., McDermott, D., Figlin, R., Berkenblit, A., Thiele, A., Krygowski, M., Strahs, A., Feingold, J., Hudes, G. (2009). Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncology: a leading journal in clinical oncology, 26.0 (2), 202-209. [More Information]
• McPherson, R., Galettis, P., de Souza, P. (2009). Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. British Journal of Cancer, 100.0(4), 649-655. [More Information]
• Crombie, C., Burns, W., Karapetis, C., Lowenthal, R., Kirsten, F., Davidson, J., Abell, F., Reece, W., Iglesias, J., de Souza, P. (2009). Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non-small-cell lung cancer: Is thrombocytopenia predictable? Asia-Pacific Journal of Clinical Oncology, 5.0(1), 24-31. [More Information]
• de Souza, P., Russell, P., Kearsley, J. (2009). Role of the akt pathway in prostate cancer. Current Cancer Drug Targets, 9.0(2), 163-175. [More Information]

2007

• Grimison, P., Galettis, P., Manners, S., Jelinek, M., Metharom, E., de Souza, P., Liauw, W., Links, M. (2007). Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: Evidence of auto-induction of gemcitabine accumulation. Journal of Clinical Oncology, 25.0 (36), 5704-5709. [More Information]

2006

• de Souza, P., Liauw, W., Links, M., Pirabhahar, S., Kelly, G., Howes, L. (2006). Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol™), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 58.0 (4), 427-433. [More Information]

2004

• Rosen, L., Gordon, D., Tchekmedyian, N., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer, 100.0(12), 2613-2621. [More Information]

2003

• Rosen, L., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al (2003). Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group. Journal of Clinical Oncology, 21.0 (16), 3150-3157. [More Information]

2001

• Diamond, T., Winters, J., Smith, A., de Souza, P., Kersley, J., Lynch, W., Bryant, C. (2001). The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study. Cancer, 92.0 (6), 1444-1450. [More Information]

2000

• Cohen, R., Mueller, S., Haden, K., De Souza, P. (2000). Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer. Cancer Investigation, 18.0 (5), 422-428. [More Information]

1997

• De Souza, P., Cooper, M., Imondi, A., Myers, C. (1997). 9-Aminocamptothecin: A topoisomerase I inhibitor with preclinical activity in prostate cancer. Clinical Cancer Research, 3.0(2), 287-294.
• De Souza, P., Castillo, M., Myers, C. (1997). Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. British Journal of Cancer, 75.0 (11), 1593-1600. [More Information]

1996

• Stea, S., Bachelor, T., Cooper, M., De Souza, P., Koenig, K., Bolton, W. (1996). Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis. Journal of the American Society of Nephrology, 7.0(11), 2399-2402.